Circulating tumour cell PD-L1 test for head and neck cancers
Head and neck squamous cell carcinoma (HNSCC) arises from a number of distinct locations in the upper aerodigestive tract, including the oral cavity, pharynx and larynx [1]. Whilst the treatment of local disease has improved over the last few decades, locoregionally advanced disease has remained a challenge, requiring a multimodal approach of surgery and chemo/radiation therapy [2,3]. Despite intensive efforts, the global 5-year survival of HNSCC remains poor (40 –50%), although in Australia this is now in excess of 60% [4,5].
Source: Oral Oncology - Category: Cancer & Oncology Authors: Arutha Kulasinghe, Liz Kenny, Chamindie Punyadeera Tags: Perspectives Source Type: research
More News: Australia Health | Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | HNSCC | Laryngeal Cancer | Oral Cancer | Oral Cavity Cancer | Pharyngeal Cancer | Radiation Therapy | Skin Cancer | Squamous Cell Carcinoma